Ozempic week 2 and lip flip: what TikTok gets wrong

What did @myshellk actually say?

She is in her second week of semaglutide injections, still on the starting dose of 0.25 mg, and plans to stay there for four weeks before moving to 0.5 mg. She reports feeling noticeably fuller on smaller portions, got nauseous after eating fair food and Chinese takeout, but says she has avoided the "terrible side effects" she had heard about. She also gave a brief lip flip update, saying she can barely see a difference at six days post-procedure.

The appetite-suppression experience she describes is specific and credible. She ate half a pint of honey chicken, a spoonful of rice, and felt done. That is a recognizable pattern from clinical data, not just anecdote. She is also transparent that she is still eating poorly at times, which matters for understanding how the drug actually works in real life.

Does the science back this up?

Yes, largely. Appetite reduction showing up this early is documented, though it varies. The SUSTAIN trials (Marso et al., 2016, New England Journal of Medicine) established that semaglutide works by activating GLP-1 receptors in the gut and brain, slowing gastric emptying and reducing appetite signaling. Some patients feel effects within the first one to two weeks.

The nausea she experienced after eating fried fair food and then Chinese takeout fits the pharmacology. Semaglutide slows how fast food leaves the stomach. High-fat, high-calorie meals stress that system. A 2022 review by Nauck and D'Alessio in Nature Reviews Endocrinology confirmed that nausea is most common in the early dose-escalation phase and is frequently triggered by dietary fat and overeating. Her description of feeling "pretty sick" after the fair is textbook early-phase GLP-1 side effects. She is not doing anything wrong by reporting it; she is accurately describing what the drug does to a lot of people.

What did they get wrong (or right)?

She got the dosing schedule right. The standard semaglutide titration for the brand-name injectable product starts at 0.25 mg for four weeks, then increases to 0.5 mg. She stumbled over the number verbally but corrected herself. That is the protocol outlined in FDA prescribing information.

What she underplays, though not incorrectly, is the cumulative nature of side effects. Saying she has avoided the "terrible side effects" at week two is accurate but incomplete. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that nausea, vomiting, and diarrhea peak during dose escalation, not necessarily at the starting dose. Week two at 0.25 mg is often the calm before the storm. Viewers interpreting her experience as representative of the full treatment course should know that side effect burden typically increases when the dose goes up.

Her injection technique detail, rotating to the abdomen to see if it makes a difference, is a reasonable personal experiment. Absorption differences between injection sites are real but clinically modest according to semaglutide pharmacokinetic data.

What should you actually know?

Feeling full faster on semaglutide is real and it shows up early for many patients, but early tolerability does not predict the full experience. The dose she is on, 0.25 mg, is a sub-therapeutic starting dose designed to minimize side effects, not to produce maximum weight loss. The appetite effects she is describing may intensify, diminish, or shift when the dose increases.

Nausea after eating high-fat or large meals is not a sign the drug is failing or harming you; it is the drug doing what it does to gastric motility. The clinical recommendation from most prescribers is to eat smaller portions, lower-fat meals, and eat slowly. This is also just good advice for GLP-1 tolerability according to practical guidance published by Garvey et al. in 2022 in Obesity.

• Do not interpret one person's week-two experience as a template for yours.
• Nausea at the fair was the food, the drug, and the combination. Any one of those alone would be less problematic.
• Lip flip results at six days are genuinely too early to assess. Most injectors say two weeks is the minimum for evaluation.

Bottom line on her claims

She is not overselling the drug. She is describing a real, documented pharmacological response without making outrageous weight-loss promises or pushing a product. The appetite reduction claim is supported by clinical evidence. The side-effect framing needs a small asterisk because her current dose is the gentlest point in the titration. If you are watching this video trying to decide whether semaglutide is right for you, her experience is a reasonable data point but talk to a prescriber before drawing conclusions from one person's week two.